Nab-Paclitaxel and Bevacizumab Followed By Bevacizumab and Erlotinib in Metastatic Breast Cancer
Conditions
- Estrogen Receptor-negative Breast Cancer
- HER2-negative Breast Cancer
- Progesterone Receptor-negative Breast Cancer
- Recurrent Breast Cancer
- Stage IV Breast Cancer
- Triple-negative Breast Cancer
Interventions
- DRUG: paclitaxel albumin-stabilized nanoparticle formulation
- BIOLOGICAL: bevacizumab
- DRUG: erlotinib hydrochloride
Sponsor
University of Washington
Collaborators